Alligator Bioscience
0.35 SEK
+76.17 %
Less than 1K followers
ATORX
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Income statement
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Alligator Bioscience
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | 4.4 | 4.4 | 12.9 | 35.7 | 58.1 | 57.8 | 0.5 |
| growth-% | -0.1 % | 197.4 % | 175.8 % | 62.8 % | -0.6 % | -99.1 % | |
| EBITDA | -203.0 | -132.8 | -130.4 | -181.0 | -238.5 | -180.4 | -95.6 |
| EBIT | -214.5 | -144.3 | -141.6 | -192.8 | -249.0 | -229.1 | -105.8 |
| Profit before taxes | -210.1 | -143.3 | -141.7 | -193.4 | -248.6 | -233.9 | -51.4 |
| Net income | -210.1 | -143.3 | -141.7 | -193.4 | -248.6 | -233.9 | -51.4 |
| EPS | -37.20 | -25.37 | -9.24 | -12.66 | -13.05 | -7.60 | -1.87 |
| Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend ratio | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % |
Profitability and return on capital
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| EBITDA-% | -4,657.4 % | -3,050.9 % | -1,007.7 % | -507.1 % | -410.4 % | -312.3 % | -18,741.8 % |
| EBIT-% | -4,922.4 % | -3,315.7 % | -1,093.8 % | -540.0 % | -428.5 % | -396.6 % | -20,750.2 % |
| ROE | -81.3 % | -124.3 % | -50.2 % | -217.2 % | -2,096.0 % | 179.1 % | -748.5 % |
| ROI | -67.5 % | -94.3 % | -42.5 % | -114.0 % | -209.9 % | -224.2 % | -46.4 % |